STAT July 6, 2021
What is the Alzheimer’s Association actually doing to get Biogen to lower its price?
If you’re like me and spend far too much time thinking about the relationships between patient groups and drug makers, you were likely shocked last month when the Alzheimer’s Association called the price of Aduhelm — a drug that the group had been promoting for months — as “simply unacceptable.” It seemed a significant shift in the relationship between drug makers and patient groups, which often are reluctant to criticize drug makers for their prices, especially when those drug makers help keep their lights on.
The statement earned the association respect from some of pharma’s fiercest critics in Washington, but increasingly both drug pricing advocates and...
Today's Sponsors
Today's Sponsor